Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)

Trial Profile

Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs BI 655130 (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 May 2018 to 26 Jun 2018.
    • 24 May 2017 Status changed from not yet recruiting to recruiting.
    • 04 May 2017 Planned initiation date changed from 24 Apr 2017 to 22 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top